Pravastatin normalizes endothelium-derived contracting factor-mediated response via suppression of Rho-kinase signalling in mesenteric artery from aged type 2 diabetic rat

Acta Physiologica

Volumn 205, Issue 2, 2012, Pages 255-265

  Ishida, K ^a   Matsumoto, T ^a   Taguchi, K ^a   Kamata, K ^a   Kobayashi, T ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Contraction; Endothelial dysfunction; Rho kinase; Statin; Type 2 diabetes

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLCHOLINE; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; EZRIN; MOESIN; PRAVASTATIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RADIXIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME REPRESSION; LONG EVANS RAT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SUPERIOR MESENTERIC ARTERY; WESTERN BLOTTING;

AGING; ANIMALS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MESENTERIC ARTERIES; PRAVASTATIN; RATS; RATS, INBRED OLETF; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84862805888     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/j.1748-1716.2011.02403.x     Document Type: Article

References (43)

1. Aalkjær, C., Boedtkjer, D. & Matchkov, V. 2011. Vasomotion - what is currently thought? Acta Physiol 202, 253-269.
2. Azekoshi, Y., Yasu, T., Watanabe, S., Tagawa, T., Abe, S., Yamakawa, K., Uehara, Y., Momomura, S., Urata, H. & Ueda, S. 2010. Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells. Hypertension 56, 136-142.
3. Bagi, Z., Erdei, N., Toth, A., Li, W., Hintze, T.H., Koller, A. & Kaley, G. 2005. Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2 derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol 25, 1610-1616.
4. Brozovich, F.V. 2003. Rho signaling: agonist stimulation and depolarization come together. Circ Res 93, 481-483.
5. Chan, C.K., Mark, J.C., Man, R.Y. & Vahnhoutte, P.M. 2009. Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta. J Pharmacol Exp Ther 329, 820-826.
6. Chen, Y., Ohmori, K., Mizukawa, M., Yoshida, J., Zeng, Y., Zhang, L., Shinomiya, K., Kosaka, H. & Kohno, M. 2007. Differential impact of atrovastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes. Circ J 71, 144-152.
7. Creager, M.A., Luscher, T.F., Cosentino, F. & Beckman, J.A. 2003. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 108, 1527-1532.
8. Denniss, S.G., Jeffery, A.J. & Ruch, J.W. 2010. RhoA-Rho kinase signaling mediates endothelium- and endoperoxide-dependent contractile activities characteristic of hypertensive vascular dysfunction. Am J Physiol Heart Circ Physiol 298, H1391-H1405.
9. Feletou, M. & Vanhoutte, P.M. 2006. Endothelial dysfunction: a multi-faceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 292, H649-H656.
10. Freeman, D.J., Norrie, J., Sattar, N., Neely, R.D., Cobbe, S.M., Ford, I., Isles, C., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H., Packard, C.J., Shepherd, J. & Gaw, A. 2001. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103, 357-362.
11. Glorioso, N., Troffa, C., Filigheddu, F., Dettori, F., Soro, A., Parpaglia, P.P., Collatina, S. & Pahor, M. 1999. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 34, 1281-1286.
12. Gluais, P., Vanhoutte, P.M. & Feletou, M. 2007. Mechanisms underlying ATP-induced endothelium-dependent contractions in the SHR aorta. Eur J Pharmacol 556, 107-114.
13. Higashi, M., Shimokawa, H., Hattori, T., Mukai, Y., Morikawa, K., Ichiki, T., Takahashi, S. & Takeshita, A. 2003. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Effect on endothelial NAD(P)H oxidase system. Circ Res 93, 767-775.
14. Ii, M. & Losordo, D.W. 2007. Statins and the endothelium. Vascul Pharmacol 46, 1-9.
15. Ito, K., Hirooka, Y., Kimura, Y., Sagara, Y. & Sunagawa, K. 2006. Ovariectomy augments hypertension through rho-kinase activation in the brain stem in female spontaneously hypertensive rats. Hypertension 48, 651-657.
16. Kagota, S., Yamaguchi, Y., Nakamura, K. & Kunitomo, M. 2000. Altered endothelium-dependent responsiveness in the aorta and renal arteries of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of non-insulin-dependent diabetes mellitus. Gen Pharmacol 34, 201-209.
17. Kajikuri, J., Watanabe, Y., Ito, R., Yamamoto, T. & Itoh, T. 2009. Characteristic changes in coronary artery at the early hyperglycemic stage in a rat type 2 diabetes model and the effects of pravastatin. Br J Pharmacol 158, 621-632.
18. Kawano, K., Hirashima, T., Mori, S., Saitoh, Y., Kurosumi, M. & Natori, T. 1992. Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41, 1422-1428.
19. Kobayashi, T., Matsumoto, T. & Kamata, K. 2000. Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. Br J Pharmacol 131, 231-238.
20. Koh, K.K., Quon, M.J., Han, S.H., Lee, Y., Kim, S.J., Park, J.B. & Shin, E.K. 2009. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 204, 483-490.
21. Masumoto, A., Hirooka, Y., Hironaga, K., Eshima, K., Setoguchi, S., Egashira, K. & Takeshita, A. 2001. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am J Cardiol 88, 1291-1294.
22. Matsui, T., Maeda, M., Doi, Y., Yonemura, S., Amano, M., Kaibuchi, K., Tsukita, S. & Tsukita, S. 1998. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140, 647-657.
23. Matsumoto, T., Kakami, M., Noguchi, E., Kobayshi, T. & Kamata, K. 2007. Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of type 2 diadetes. Am J Physiol Heart Circ Physiol 293, H1480-H1490.
24. Matsumoto, T., Noguchi, E., Ishida, K., Kobayashi, T., Yamada, N. & Kamata, K. 2008. Metformin normalized endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 295, H1165-H1176.
25. Matsumoto, T., Ishida, K., Nakayama, N., Taguchi, K., Kobayshi, T. & Kamata, K. 2010. Mechanisms underlying the losartan treatment-induced improvement in the endothelial dysfunction seen in mesenteric arteries from type 2 diabetic rats. Pharmacol Res 62, 271-281.
26. Matsuzaki, G., Ishizaka, N., Furuta, K., Hongo, M., Saito, K., Sakurai, R., Koike, K. & Nagai, R. 2008. Comparison of vasculoprotective effects of benidipine and losartan in a rat model of metabolic syndrome. Eur J Pharmacol 587, 237-242.
27. Mizukawa, M., Ohmori, K., Obayashi, A., Ishihara, Y., Yoshida, J., Noma, T., Yukiiri, K., Kosaka, H. & Kohno, M. 2009. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model. Hypertens Res 32, 617-624.
28. Nohria, A., Prsic, A., Liu, P.Y., Okamoto, R., Creager, M.A., Selwyn, A., Liao, J.K. & Ganz, P. 2009. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205, 517-521.
29. Nuno, D.W., Korovkina, V.P., England, S.K. & Lamping, K.G. 2007. RhoA activation contributes to sex differences in vascular contractions. Arterioscler Thromb Vasc Biol 27, 1934-1940.
30. Ohkawara, H., Ishibashi, T., Saitoh, S., Inoue, N., Sugimoto, K., Kamioka, M., Uekita, H., Kaneshiro, T., Ando, K., Takuwa, Y., Maruyama, Y. & Takeishi, Y. 2010. Preventive effects of pravastatin on thrombin-triggered vascular responses via Akt/eNOS and RhoA/Rac1 pathways in vivo. Cardiovasc Res 88, 492-501.
31. Pannirselvam, M., Wiehler, W.B., Anderson, T. & Triggle, C.R. 2005. Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. Br J Pharmacol 144, 953-960.
32. Rakotoniaina, Z., Guerard, P., Lirussi, F., Goirand, F., Rochette, L., Dumas, M. & Bardou, M. 2006. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atrovastatin. Naunyn Schmiedebergs Arch Pharmacol 374, 195-206.
33. Shimokawa, H. & Takeshita, A. 2005. Rho kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25, 1767-1775.
34. Sowers, J.R. 2004. Insulin resistance and hypertension. Am J Physiol 286, H1597-H1602.
35. Steinberg, H.O., Tarshoby, M., Monestel, R., Hook, G., Cronin, J., Johnson, A., Bayazeed, B. & Baron, A.D. 1997. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100, 1230-1239.
36. Takemoto, M. & Liao, J.K. 2001. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 21, 1712-1719.
37. Tang, E.H. & Vanhoutte, P.M. 2009. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 122, 140-149.
38. Tesauro, M. & Cardillo, C. 2011. Obesity, blood vessels and metabolic syndrome. Acta Physiol 203, 279-286.
39. Vanhoutte, P.M., Shimokawa, H., Tang, E.H. & Feletou, M. 2009. Endothelial dysfunction and vascular disease. Acta Physiol 196, 193-222.
40. Xu, Z., Okamoto, H., Akino, M., Onozuka, H., Matsui, Y. & Tsutsui, H. 2008. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol 51, 62-70.
41. Yamanouchi, D., Banno, H., Nakayama, M., Sugimoto, M., Fujita, H., Kobayashi, M., Kuwano, H. & Komori, K. 2005. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J Vasc Surg 42, 757-764.
42. Yamamoto, E., Yamashita, T., Tanaka, T., Kataoka, K., Tokutomi, Y., Lai, Z.F., Dong, Y.F., Matsuba, S., Ogawa, H. & Mitsuyama, S.K. 2007. Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 27, 556-563.
43. Yu, Y., Ohmori, K., Chen, Y., Sato, C., Kiyomoto, H., Shinomiya, K., Takeuchi, H., Mizushige, K. & Kohno, M. 2004. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetic model. J Am Coll Cardiol 44, 904-913.